(PharmaNewsWire.Com, March 20, 2017 ) According to Publisher, the Bone Marrow Transplant market accounted for $10.58 billion in 2015 and is expected to reach $15.95 billion by 2022 growing at a CAGR of 6.0% from 2015 to 2022. Occurrence of blood cancers and increasing investment in logistic services are the key factors fueling the market growth. On the other hand, high cost of the treatment and uncertainty of reimbursement in several developing countries are the key factors hampering the market growth.
With more than 60% of the total market share in 2014, Autologous segment leads the global bone marrow transplant market due to the less considerable side effects. Allogeneic is anticipated to grow at the highest CAGR during the forecast period. Europe dominated the global market for bone marrow transplant accounting for more than 50% of the market revenue followed by North America.
Some of the key players in the market include Lonza Group Ltd., Cellular Dynamics International, Merck Millipore Corporation, ABM Industries, Inc., HemaCare Corporation, ReachBio LLC, American Type Culture Collection (ATCC) Inc., Conversant Biologics, Inc., PromoCell GmbH, Sanofi-Aventis LLC, AllCells, LLC, Mesoblast Limited, STEMCELL Technologies Inc. and Lifeline Cell Technology.
Transplant Type Covered: -Allogeneic Bone Marrow Transplant -Autologous Bone Marrow Transplant
End Users Covered: -Multispecialty Clinics -Hospitals -Ambulatory Surgery Centers
Regions Covered: -North America -US -Canada -Mexico -Europe -Germany -France -Italy -UK -Spain -Rest of Europe -Asia Pacific -Japan -China -India -Australia -New Zealand -Rest of Asia Pacific -Rest of the World -Middle East -Brazil -Argentina -South Africa -Egypt
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including: